Antibiotic Development: ‘Wildcard Exclusivity’ Proposal Returns

Economic ‘pull’ incentives that don’t require direct government spending draw support from industry and academic stakeholders.

Before the surprise election of Donald Trump to be president, creating new incentives for antibiotic development had been seen as one area of potential bipartisan agreement on health policy. That’s still true, but any solutions that are created will have a much more Republican favor.

At a forum on economic incentives for antimicrobials held Nov. 9, the day after the election, Gregory Daniel, deputy director...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America